NovaBay Pharmaceuticals, Inc.
NBY · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $521 | $0 | $0 | $2,309 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $479 | $0 | $0 | $807 |
| Gross Profit | $42 | $0 | $0 | $1,502 |
| % Margin | 8.1% | – | – | 65% |
| R&D Expenses | $0 | $0 | $0 | $10 |
| G&A Expenses | $1,211 | $1,891 | $2,701 | $1,768 |
| SG&A Expenses | $1,211 | $1,891 | $2,701 | $2,781 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $1,013 |
| Other Operating Expenses | $87 | $0 | $589 | $0 |
| Operating Expenses | $1,298 | $1,891 | $3,290 | $2,791 |
| Operating Income | -$1,256 | -$1,891 | -$3,290 | -$1,289 |
| % Margin | -241.1% | – | – | -55.8% |
| Other Income/Exp. Net | -$77 | -$73 | -$40 | -$34 |
| Pre-Tax Income | -$1,333 | -$1,964 | -$3,330 | -$1,323 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1,293 | -$1,922 | $7,670 | -$1,212 |
| % Margin | -248.2% | – | – | -52.5% |
| EPS | -0.22 | -0.33 | 1.44 | -0.27 |
| % Growth | 33.3% | -122.9% | 633.3% | – |
| EPS Diluted | -0.22 | -0.33 | 1.42 | -0.27 |
| Weighted Avg Shares Out | 5,876 | 5,818 | 5,308 | 4,885 |
| Weighted Avg Shares Out Dil | 5,876 | 5,818 | 5,415 | 4,885 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $55 | $0 | $33 |
| Depreciation & Amortization | $2 | $38 | $55 | $95 |
| EBITDA | -$1,331 | -$1,926 | -$3,275 | -$1,195 |
| % Margin | -255.5% | – | – | -51.8% |